Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcome measures in multiple sclerosis clinical trials.

P B Andersson1, D E Goodkin

  • 1Department of Neurology, Stanford University Medical Center, CA 94305-5235, USA.

Bailliere'S Clinical Neurology
|April 2, 1999
PubMed
Summary

Multiple sclerosis (MS) treatment trials require effective outcome measures. This review discusses ideal properties, current clinical, radiological, and laboratory measures, and future directions for MS trial design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.

Journal of neurology, neurosurgery, and psychiatry·2003
Same author

T2 relaxation time histograms in multiple sclerosis.

Magnetic resonance imaging·2003
Same author

3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain.

Magnetic resonance imaging·2002
Same author

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Neurology·2002
Same author

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Neurology·2002
Same author

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis.

Journal of consulting and clinical psychology·2002

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Multiple sclerosis (MS) is an incurable neurological disease.
  • Developing effective treatments for MS necessitates rigorous clinical trials.
  • There is a growing need for efficient and reliable outcome measures to assess therapeutic efficacy in MS.

Purpose of the Study:

  • To discuss the characteristics of an ideal outcome measure for MS treatment trials.
  • To review the strengths and limitations of existing outcome measures (clinical, radiological, laboratory).
  • To provide recommendations for outcome measure selection and future trial design in MS.

Main Methods:

  • Literature review of existing outcome measures in multiple sclerosis research.
  • Discussion of the properties of an ideal outcome assessment tool.
  • Analysis of current consensus and future perspectives in clinical trial design for MS.

Main Results:

  • Identified key properties of an ideal outcome measure for MS.
  • Evaluated the advantages and disadvantages of current clinical, radiological, and laboratory outcome measures.
  • Synthesized current recommendations for outcome measure selection in MS trials.

Conclusions:

  • The selection of appropriate outcome measures is critical for the success of multiple sclerosis treatment trials.
  • A comprehensive understanding of available measures is essential for researchers and clinicians.
  • Future research should focus on refining existing measures and developing novel approaches for MS outcome assessment.

Related Experiment Videos